1 APRIL 2022 ausdoc . com . au
Aussie blood types changing
RhD-negative donors declining . |
|
|
|
|
Siobhan Calafiore CHANGES in the prevalence of certain
blood types in Australia as a result of immigration may make it increasingly challenging to find RhD-negative blood donors , the national blood supplier says .
In the first analysis of blood group distribution in nearly 30 years , the Australian Red Cross Lifeblood tracked data from 1.3 million patients who underwent blood pathology testing in 2019 , as well as data from around half a million blood donors .
|
|
|
|
They found only 14 % of the population had a negative blood type , and just 6.5 % were O-negative , compared with 19 % and 9 % respectively in 1993-94 , it found . Over the same 25-year period , the number of firsttime RhD-positive blood donors increased from 81 % to 84 %.
Compared with previous estimates , B-positive increased the most from 8 % to 12 % of the donor population , while AB-positive increased from 2 % to 4 %.
“ These findings suggest that the
|
|
|
proportion of RhD-positive blood group donations is increasing at the expense of RhD-negative red blood cell units ,” the researchers wrote in the Medical Journal of Australia . “ Our findings highlight the challenge of meeting the increasing demand for RhD-negative red blood cells .”
The team , led by Dr Rena Hirani from Lifeblood and Macquarie University , noted a rise in immigration from South-East Asia , India and China during the past 10 years , where
|
|
prevalence of the B and AB blood groups was generally higher . The shift in blood group distribution was also reflected in the changing demand for red blood cell units , they added .
Other findings showed the proportion of units issued for O-negative blood types increased sharply from 12 % to 17 % in the past decade , while units issued for B-positive and AB-positive declined .
Dr Hirani said the findings would help with supply forecasts . Med J Aust 2022 ; 21 Mar .
|
|
|
|
|
No regrets for health watchdog |
Quadrivalent influenza vaccine ( surface antigen , inactivated , prepared in cell cultures )
Not all influenza vaccines
1
are the same
Help him make the choice .
FLUCELVAX ® QUAD :
• Designed to be an exact match to WHO-selected strains 2-5 †
† May not predict clinical effects
• Eliminates egg-adaptation 3 , 6 , 7 which may impact vaccine match to WHO-selected strains and vaccine effectiveness in some seasons . 3 , 6 – 8
Recommend FLUCELVAX ® QUAD for patients 2 years and older 9
WHO : World Health Organisation
PBS Information : This product is not listed on the National Immunisation Program ( NIP ) or the PBS .
Before prescribing , please review Product Information available at www . seqirus . com . au / products
MINIMUM PRODUCT INFORMATION Flucelvax ® Quad ( Inactivated Quadrivalent Influenza Vaccine ( prepared in cell cultures )) - Suspension for injection . Indication : For the prevention of influenza caused by Influenza Virus , Types A and B contained in the vaccine , for use in adults and children 2 years of age and older . Contraindications : Individuals with known severe allergic reactions ( e . g . anaphylaxis ) to any component of the vaccine or to a previous dose of any influenza vaccine . Precautions : Treatment and supervision for anaphylactic reactions should be available . Antibody response in immunocompromised patients may be lower . Careful consideration for use in history of Guillain-Barré syndrome within 6 weeks of previous influenza vaccination . Postpone immunisation in patients with febrile illness or acute infection . A protective immune response may not be elicited in all vaccine recipients . Use in Pregnancy ( Category B1 ): The safety of Flucelvax ® Quad in pregnancy has not been assessed in clinical trials . There are no reproductive and developmental toxicity studies with Flucelvax ® Quad . Reproductive and developmental toxicity data from cell-based trivalent influenza vaccine ( TIVc ) do not predict an increased risk of developmental abnormalities . Use in Lactation : Not been evaluated in nursing mothers . Interactions : No data available on co-administration with other vaccines . Based on clinical experience with TIVc , Flucelvax ® Quad can be given at the same time as other vaccines ( in separate limbs ) ( adverse reactions may be intensified ). Adverse Effects : Local - pain , erythema . Systemic - headache , fatigue , irritability ( children 2-6 years ), upper respiratory tract infection , nasopharyngitis ( See full PI ). Dosage and Administration : Intramuscular injection only : single 0.5mL dose ( children < 9 years may require 2 doses - see full PI ). Presentation : 0.5mL single-use syringe . Storage : Store at 2 ° C to 8 ° C ; must not be frozen ; protect from light . Based on Approved Product Information .
References : 1 . ATAGI . Statement on the administration of seasonal influenza vaccines in 2022 . www . health . gov . au / resources / publications / atagi-advice-on-seasonal-influenza-vaccines-in-2022 Accessed January 2022 . 2 . Rajaram S et al . Ther Adv Vaccines Immunother . 2020 ; 8:2515135520908121 . 3 . CDC . Cell-based flu vaccines . Available from : www . cdc . gov / flu / prevent / cell-based . htm Accessed January 2022 . 4 . Mabrouk T et al . Dev Biol ( Basel ). 2002 ; 110:125 – 134 . 5 . WHO . Influenza A ( H3N2 ) lineage cell culture-derived CVVs for development and production of vaccines for use in the 2022 SH influenza season ; Available from : https :// cdn . who . int / media / docs / default-source / influenza / cvvs / cvv-southern-hemisphere-2022 / a ( h3n2 ) ---cell-culture-derived . pdf Accessed January 2022 . 6 . Skowronski DM et al . PLoS One . 2014 ; 9 ( 3 ): e92153 . 7 . Rajaram S et al . Int J Environ Res Public Health . 2020 ; 17 ( 15 ): 5423 . 8 . Paules CI et al . N Engl J Med . 2018 ; 378 ( 1 ): 7 – 9 . 9 . FLUCELVAX ® QUAD Approved Product Information .
Seqirus ( Australia ) Pty Ltd Melbourne , Victoria . ABN : 66 120 398 067 . www . seqirus . com . au . Seqirus Medical Information : 1800 642 865 . FLUCELVAX ® is a registered trademark of Seqirus UK or its affiliates . Seqirus™ is a trademark of Seqirus UK Limited or its affiliates . Date of preparation : January 2022 . ANZ-QIVc-22-0003 . 001232-ADG-B . .
FROM PAGE 1 constructive communication ” and to “ reflect on and improve your practice ”.
It triggered a backlash from many doctors , who said Dr Holliday , who practises in Taree , was being censured without being given the opportunity to defend himself .
But the commission defended its actions , telling Australian Doctor it had acted because Dr Holliday had made “ inappropriate assumptions ” and had used “ language about patients which had caused offence and were not considered professional ”.
‘ If it was a Facebook post saying Dr Holliday is a bum or a terrible person , I wouldn ’ t really care .’
“ Comments of the kind made to this practitioner are for the purposes of encouraging reflection and do not have any bearing on , or relationship to , current or future disciplinary proceedings ,” it added .
But Dr Holliday said : “ If it was a Facebook post saying Dr Holliday is a bum or a terrible person , I wouldn ’ t really care .
“ But if it ’ s the body that is meant to be policing ethics , standards and professionalism … it ’ s my opinion they should show at least a minimal degree of those qualities .”
“ Why aren ’ t they prepared to say , ‘ We stuffed up ?’”
001232 Flucelvax Quad In Season HCP Ad 210x273 _ v7 _ 01 – FA . indd 2 28 / 2 / 22 4:58 pm